DA1 receptors modulation in rat isolated trachea

American Journal of Therapeutics

Volumn 17, Issue 3, 2010, Pages 301-305

  Cabezas, Gloria A ^a   Velasco, Manuel ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Airway DA1 receptor; Airway dopamine receptors; Dopamine tracheal relaxation

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; METOCLOPRAMIDE; PROPRANOLOL; TERAZOSIN; YOHIMBINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; ELECTROSTIMULATION; INCUBATION TIME; MALE; MULTICHANNEL RECORDER; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; SPRAGUE DAWLEY RAT; TRACHEA MUSCLE; ANIMAL; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MUSCLE CONTRACTION; SMOOTH MUSCLE; TRACHEA;

ACETYLCHOLINE; ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TRACHEA; VASODILATOR AGENTS;

EID: 77952485905     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c122fa     Document Type: Article

References (10)

1. Michoud MC, Amyot R, Jeanneret-Grosjean A. Dopamine effect on bronchomotor tone in vivo. Am Rev Respir Dis. 1984;130:755-758.
2. Cabezas GA, Lezama Y, Vidal A, et al. Inhaled dopamine induces bronchodilatation in patients with bronchial asthma. Int J Clin Pharmacol Ther. 1999;37:510-513.
3. Cabezas GA, Lezama Y, Velasco M. Dopaminergic modulation of human bronchial tone. Arch Med Res. 2001;32:143-147.
4. Cabezas GA, Israili ZH, Velasco M. The actions of dopamine on the airways. Am J Ther. 2003;10:477-486.
5. Kamikawa Y, Shimo Y. Inhibitory effects of catecholamines on cholinergically and non-cholinergically mediated contractions of guinea-pig isolated bronchial muscle. J Pharm Pharmacol. 1990;41:131-134. (Pubitemid 20238645)
6. Birrell MA, Crispino N, Hele DJ, et al. Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002;136:620-628.
7. Peiser C, Trevisani M, Groneberg DA, et al. Dopamine type 2 receptor expression and function in rodent sensory neurons projecting to the airways. Am J Physiol Lung Cell Mol Physiol. 2005;289: L153-L158.
8. Bonnert RV, Brown RC, Chapman D, et al. Dual D2- receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7- (2-aminoethyl) -4 hydroxybenzothiazol-2 (3H) - one analogues. J Med Chem. 1998;41:4915-4917.
9. Laursen LC, Lindqvist A, Hepburn T, et al. The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir Med. 2003;97(Suppl A): S23-S33.
10. Ind PW, Laitinen L, Laursen L, et al. Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms. Respir Med. 2003;97(Suppl A): S9-S21.